As HHS Secretary, Kennedy cut nearly $500 million in funding for mRNA vaccine research. While he says that the decision was made after looking at the science, health experts have heavily criticized ...

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives ...

The clinical hold is due to questions about BX004’s nebulizer device, temporarily pausing US enrollment in the cystic ...

The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA ...

EMD Serono recently named Miguel Fernandez Alcalde as its new president. The new executive spoke with Pharmaceutical ...

The MFN executive order introduces uncertainty in pharma pricing strategies, necessitating careful risk assessment and ...

Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage ...

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

Why pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support ...